Puretech Health Financials
This page shows Puretech Health (PRTC) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Puretech Health's revenue surged 45.0% year-over-year to $4.8M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Puretech Health carries a low D/E ratio of 0.04, meaning only $0.04 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 9.33, Puretech Health holds $9.33 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While Puretech Health generated -$134.4M in operating cash flow, capex of $11K consumed most of it, leaving -$134.4M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Puretech Health generates a 6.8% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 26/100. This is up from -14.5% the prior year.
Puretech Health passes 6 of 9 financial strength tests. 2 of 4 profitability signals pass, all 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Puretech Health generates $-4.84 in operating cash flow (-$134.4M OCF vs $27.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Puretech Health generated $4.8M in revenue in fiscal year 2024. This represents an increase of 45.0% from the prior year.
Puretech Health reported $27.8M in net income in fiscal year 2024. This represents an increase of 141.7% from the prior year.
Cash & Balance Sheet
Puretech Health generated -$134.4M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 26.8% from the prior year.
Puretech Health held $280.6M in cash against $14.7M in long-term debt as of fiscal year 2024.
Puretech Health had 239M shares outstanding in fiscal year 2024. This represents a decrease of 11.9% from the prior year.
Margins & Returns
Puretech Health's net profit margin was 575.4% in fiscal year 2024, showing the share of revenue converted to profit. This is up 2576.3 percentage points from the prior year.
Puretech Health's ROE was 6.8% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is up 21.3 percentage points from the prior year.
Capital Allocation
Puretech Health spent $4.8M on share buybacks in fiscal year 2024, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 75.6% from the prior year.
Puretech Health invested $11K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 84.3% from the prior year.
PRTC Income Statement
| Metric | Q4'24 | Q2'24 | Q4'23 | Q4'22 | Q4'21 | Q4'20 | Q4'19 | Q4'18 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Income | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
PRTC Balance Sheet
| Metric | Q4'24 | Q2'24 | Q4'23 | Q4'22 | Q4'21 | Q4'20 | Q4'19 | Q4'18 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $602.6M+3.9% | $580.0M-16.4% | $694.0M-1.2% | $702.6M-25.7% | $946.0M-4.4% | $990.0M+5.2% | $941.2M | N/A |
| Current Assets | $386.3M-24.1% | $508.8M+46.5% | $347.2M-10.1% | $386.2M-23.0% | $501.8M+21.1% | $414.3M+145.4% | $168.8M | N/A |
| Cash & Equivalents | $280.6M-9.0% | $308.5M+61.4% | $191.1M+27.5% | $149.9M-67.8% | $465.7M+15.3% | $403.9M+205.1% | $132.4M+13.1% | $117.1M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $1.5M-25.9% | $2.1M-13.5% | $2.4M-80.0% | $11.9M+273.9% | $3.2M+24.1% | $2.6M+29.4% | $2.0M | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $194.7M-28.9% | $273.7M+16.1% | $235.7M+52.0% | $155.1M-57.1% | $361.9M+7.6% | $336.5M+15.7% | $290.8M | N/A |
| Current Liabilities | $41.4M-70.1% | $138.3M+169.3% | $51.4M-47.0% | $96.9M-57.2% | $226.1M+25.0% | $180.9M+30.0% | $139.2M | N/A |
| Long-Term Debt | $14.7M-10.7% | $16.4M-10.0% | $18.3M-24.4% | $24.2M-16.8% | $29.0M-9.5% | $32.1M-8.1% | $34.9M | $0 |
| Total Equity | $407.9M+33.2% | $306.2M-33.2% | $458.2M-16.3% | $547.6M-6.3% | $584.1M-10.6% | $653.5M+0.5% | $650.4M+287.2% | $168.0M |
| Retained Earnings | $32.5M+152.0% | -$62.5M-174.6% | $83.8M-43.9% | $149.5M-25.2% | $199.9M-23.3% | $260.4M+2.4% | $254.4M | N/A |
PRTC Cash Flow Statement
| Metric | Q4'24 | Q2'24 | Q4'23 | Q4'22 | Q4'21 | Q4'20 | Q4'19 | Q4'18 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
PRTC Financial Ratios
| Metric | Q4'24 | Q2'24 | Q4'23 | Q4'22 | Q4'21 | Q4'20 | Q4'19 | Q4'18 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | 9.33+5.7 | 3.68-3.1 | 6.76+2.8 | 3.99+1.8 | 2.22-0.1 | 2.29+1.1 | 1.21 | N/A |
| Debt-to-Equity | 0.04-0.0 | 0.05+0.0 | 0.040.0 | 0.040.0 | 0.050.0 | 0.050.0 | 0.05+0.1 | 0.00 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Puretech Health's annual revenue?
Puretech Health (PRTC) reported $4.8M in total revenue for fiscal year 2024. This represents a 45.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Puretech Health's revenue growing?
Puretech Health (PRTC) revenue grew by 45% year-over-year, from $3.3M to $4.8M in fiscal year 2024.
Is Puretech Health profitable?
Yes, Puretech Health (PRTC) reported a net income of $27.8M in fiscal year 2024, with a net profit margin of 575.4%.
How much debt does Puretech Health have?
As of fiscal year 2024, Puretech Health (PRTC) had $280.6M in cash and equivalents against $14.7M in long-term debt.
What is Puretech Health's net profit margin?
Puretech Health (PRTC) had a net profit margin of 575.4% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Puretech Health's return on equity (ROE)?
Puretech Health (PRTC) has a return on equity of 6.8% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Puretech Health's free cash flow?
Puretech Health (PRTC) generated -$134.4M in free cash flow during fiscal year 2024. This represents a -26.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Puretech Health's operating cash flow?
Puretech Health (PRTC) generated -$134.4M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Puretech Health's total assets?
Puretech Health (PRTC) had $602.6M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Puretech Health's capital expenditures?
Puretech Health (PRTC) invested $11K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
What is Puretech Health's current ratio?
Puretech Health (PRTC) had a current ratio of 9.33 as of fiscal year 2024, which is generally considered healthy.
What is Puretech Health's debt-to-equity ratio?
Puretech Health (PRTC) had a debt-to-equity ratio of 0.04 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Puretech Health's return on assets (ROA)?
Puretech Health (PRTC) had a return on assets of 4.6% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Puretech Health's cash runway?
Based on fiscal year 2024 data, Puretech Health (PRTC) had $280.6M in cash against an annual operating cash burn of $134.4M. This gives an estimated cash runway of approximately 25 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Puretech Health's Piotroski F-Score?
Puretech Health (PRTC) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Puretech Health's earnings high quality?
Puretech Health (PRTC) has an earnings quality ratio of -4.84x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Puretech Health?
Puretech Health (PRTC) scores 65 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.